Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate

International Journal of Gynecological Pathology

Volumn 31, Issue 6, 2012, Pages 556-569

  Williams, Alistair R W ^a   Bergeron, Christine ^c   Barlow, David H ^b   Ferenczy, Alex ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LABORATOIRE CERBA   (France)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Endometrium; Fibroids; Histopathology; Myomas; PRM associated endometrial changes (PAEC); Progesterone receptor modulators; Ulipristal acetate

Indexed keywords

GONADORELIN AGONIST; ULIPRISTAL;

ADULT; APOPTOSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THICKNESS; TREATMENT DURATION; UTERUS BLEEDING; UTERUS MYOMA;

ADOLESCENT; ADULT; BIOPSY; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; LEIOMYOMA; MIDDLE AGED; NORPREGNADIENES; RECEPTORS, PROGESTERONE;

EID: 84867405170     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318251035b     Document Type: Article

References (26)

1. Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307.
2. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38.
3. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-420.
4. Donnez J, Tomaszewski J, Vá zquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-432.
5. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-8.
6. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: Changes and consequences. Hum Reprod Update 2007;13:567-80.
7. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97:734-9.
8. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995;85:977-82.
9. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen/ Progestin Drug: Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation. Rockville, MD: Center for Drug Evaluation and Research (CDER); 2013. Available at: Fttp:// www.fda.gov/cder/guidance/index.htm.
10. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebocontrolled trial. J Clin Endocrinol Metab 2007;92:3582-9.
11. Williams ARW, Bergeron C, Chabbert-Buffet N, et al. Progesterone receptor modulator associated endometrial changes: A pilot histological dose escalation study of ulipristal acetate. Facts, Views and Vision in ObGyn; Sci J Flemish Soc Obstet Gynecol 2010, abstract 163, EBCOG, Antwerp, p. 99.
12. Kelly RW, King AE, Critchley HOD. Inflammatory mediators and endometrial function - focus on the perivascular cell. J Reprod Immunol 2002;57:81-93.
13. Baird DT, Brown A, Critchley HOD, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-8.
14. Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-704.
15. Hodgen GD, van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994;9(SUPPL1): 77-81.
16. Chwalisz K, Brenner RM, Fuhrmann UU, et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65:741-51.
17. Brenner RM, Slayden OD, Nath A, et al. Intrauterine administration of CDB-2914 (ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010;81:336-42.
18. Baird DT, Brown A, Critchley HOD, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-8.
19. Croxatto HB, Ková cs L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998;13:793-8.
20. Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogenfree oral contraceptive pill for women: Multicentre, doubleblind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22: 2428-36.
21. Fiscella J, Bonfiglio T, Winters P, et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011;42:947-53.
22. Heikinheimo O, Vani S, Carpe'n O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: A pilot study. Hum Reprod 2007;22:2515-22.
23. Mutter GL, Olga B, Ioffe R, et al. Proellex effects on the endometrium. Gynecol Endocrinol 2008;24(SUPPL1): 75.
24. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22:450-9.
25. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001;86:2668-79.
26. Heikinheimo O, Hsiu JG, Gordon K, et al. Endometrial effects of RU486 in primates - antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J Steroid Biochem Mol Biol 1996;59:179-90.